Case Report: Dabigatran-Associated Gynecologic Bleeding
Authors:
- 1 March 2013
- journal article
- research article
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 48 (3) , 227-230
Abstract
Purpose: The case of a patient who experienced major gynecological bleeding after initiation of dabigatran therapy for atrial fibrillation is reported. Summary: A 33-year-old Hispanic female with multiple medical problems presented to the emergency department (ED) with a 5-day history of menorrhagia and a 3-day history of dizziness, fatigue, and weakness. Prior to ED presentation, she had been initiated on dabigatran 150 mg twice daily for atrial fibrillation. Four days later, she began having profuse vaginal bleeding. She discontinued all of her home medications including dabigatran, and her bleeding subsided the next day. Upon presentation to the ED, her hemoglobin was 7.1 g/dL, for which she was transfused 2 units of packed red blood cells, increasing her hemoglobin to 9.6 g/dL. Because the patient was in atrial fibrillation, warfarin was initiated once she was clinically stable and she was never restarted on dabigatran. Her hemoglobin was stable throughout admission with no further bleeding. She was discharged on warfarin and closely followed without incident. Conclusion: A 33-year-old Hispanic female with no pre-existing gynecologic abnormalities had a major gynecological bleed shortly after starting dabigatran that resolved after discontinuation.Keywords
This publication has 10 references indexed in Scilit:
- 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)JACC, 2011
- Dispatcher-Assisted Cardiopulmonary ResuscitationCirculation, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic DiseasesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran EtexilateClinical Pharmacokinetics, 2008
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Lifetime Risk for Development of Atrial FibrillationCirculation, 2004
- Validation of Clinical Classification Schemes for Predicting StrokeJAMA, 2001
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981